arrow
A

Andrés Redondo

hospital universitario la paz idipaz
H指数:45
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

MAINTENANCE DOSTARLIMAB AFTER CHEMORADIATION (CRT) FOR PATIENTS WITH HIGH-RISK LOCALLY ADVANCED CERVICAL CANCER: GEICO 78-C/ATOMICC RANDOMIZED PHASE 2 TRIAL

化疗放疗(CRT)后对高风险局部晚期宫颈癌患者进行度伐利尤单抗维持治疗:GEICO 78-C/ATOMICC 随机II期试验

2026-10-040
PRE
Diagnosis and Therapy of Soft Tissue Sarcomas: Spanish Group for Research in Sarcomas (GEIS) Guidelines

软组织肉瘤的诊断与治疗:西班牙肉瘤研究组(GEIS)指南

2025-09-290
OAAI
Dostarlimab and niraparib in primary advanced ovarian cancer

多斯塔利姆单抗和尼拉帕利在原发性晚期卵巢癌中的应用

2025-06-020
OAAI
An ambispective, real-world multi-center study of DOstarlimab in patients with Recurrent or Advanced DNA mismatch repair deficient/microsatellite instability-high endometrial cancer (GEICO 120-R/DORA study)

一项关于DOstarlimab在复发性或晚期DNA错配修复缺陷/微卫星高度不稳定子宫内膜癌患者中的前瞻性、真实世界、多中心研究(GEICO 120-R/DORA研究)

2025-04-260
PRE
ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety

ENGOT-OV16/NOVA试验中 niraparib 治疗复发卵巢癌的生存率与长期安全性

2025-04-010
PRE
Palbociclib plus letrozole in estrogen receptor-positive advanced/ recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial

帕博西利联合来曲唑在雌激素受体阳性晚期/复发性子宫内膜癌中的应用:双盲安慰剂对照随机II期ENGOT-EN3/PALEO试验

2025-01-011
OAAI
Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single-arm, phase 2 trial
CANCER
IF5.1
2024-11-141
PRE
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ ENGOT-OV26/GOG-3012 trial

新诊断晚期卵巢癌患者的尼拉帕尼一线维持治疗: PRIMA/ ENGOT-OV26/GOG-3012试验的最终总生存期结果

2024-11-012
OAAI
Final overall survival (OS) in patients (pts) with newly diagnosed advanced ovarian cancer (aOC) treated with niraparib (nir) first-line (1L) maintenance: Results from PRIMA/ENGOT-OV26/GOG-3012

新诊断的晚期卵巢癌(aOC)患者(pts)接受尼拉帕利(nir)一线(1L)维持治疗后的最终总生存期(OS)结果:来自PRIMA/ENGOT-OV26/GOG-3012研究

2024-09-011
PRE
IMMUNOSARC II master trial (phase II of sunitinib and nivolumab): Results from the clear cell sarcoma (CCS) cohort: A GEIS, ISG, and UCL study

IMMUNOSARC II主试验(舒尼替尼和纳武利尤单抗的II期):透明细胞肉瘤(CCS)队列的结果:一项GEIS、ISG和UCL研究

2024-09-010
PRE
Prognostic impact of tumor location and gene expression profile in sporadic desmoid tumor
2024-09-010
PRE
Factors influencing awareness of patient associations in sarcoma: A multicentric cross-sectional study

影响软组织肉瘤患者协会意识的因素:一项多中心横断面研究

2024-09-010
PRE
Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer

mirvetuximab soravtansine联合贝伐单抗与贝伐单抗在fra-高铂敏感性卵巢癌中的维持治疗

2024-07-313
OAAI
Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - a plain language summary

随访3.5年时的无进展生存期和安全性: 对新诊断卵巢癌患者进行尼拉帕尼维持治疗的3期PRIMA/ENGOT-OV26/GOG-3012随机试验的结果-简明语言总结

2024-03-191
OAAI
Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ ENGOT-ov38): a phase IIIb trial

先前接受PARP抑制剂 (OReO/ ENGOT-ov38) 治疗的铂敏感复发性卵巢癌患者的维持olaparib再激发: IIIb期试验

2023-12-0123
OA
Efficacy of immune checkpoint inhibitors in alveolar soft-part sarcoma: results from a retrospective worldwide registry
2023-12-016
OAAI